Does Medicare Cover Osphena? What Part D Actually Pays in 2026

Medicare can cover Osphena through a stand-alone Part D plan or a Medicare Advantage plan with drug coverage. Original Medicare's routine Part A/B benefit does not normally cover a retail Osphena prescription. Your result depends on the exact formulary, tier, restrictions, pharmacy, deductible, and the indication documented in any coverage request.

Affiliate disclosure: this page contains one clearly marked Midi Health affiliate link near the end. The Medicare coverage checks, sources, and action steps are non-affiliate.

Yes, the door is open. No, that does not mean every plan pays.

We opened four real 2026 Medicare plan formularies and four public payer criteria documents. The plan documents put Osphena on different tiers, but all four required prior authorization. The payer criteria went from no prerequisite treatment trials to three. One current commercial guideline approves only vaginal dryness and says painful sex could be a benefit exclusion—even though CMS clarified in 2018 that menopause-related dyspareunia is not excluded from Part D when the drug is used consistently with its FDA labeling.

Same 60 mg tablet. Very different paperwork.

Below is everything we verified, with document names, dates, and the limits of what each source can prove.

Is this page for you?

This page is for a Medicare beneficiary who has an Osphena prescription, a rejected claim, or a plan-choice problem to solve. It is not a treatment recommendation, and it is not the place to decide whether Osphena is safe or appropriate for your medical history.

Yes, if:

• Your pharmacy just rejected Osphena or quoted a price that made you put it back.
• You recently moved onto Medicare and the commercial savings card stopped working.
• Your clinician prescribed Osphena and you want to check coverage before you fill it.
• You are comparing Medicare plans and Osphena is on your medication list.
• Your plan says prior authorization, step therapy, quantity limit, or nonformulary—and you need to know what that actually means.

Not for you if:

• You have commercial insurance and are checking the commercial copay card. This page is about Medicare rules; use the current manufacturer terms for your plan type.
• You have not seen a clinician and are trying to decide whether Osphena is medically appropriate.
• You have unexplained vaginal bleeding, an estrogen-dependent cancer, an active or past blood clot, stroke, or heart attack, or known or possible pregnancy. Those are FDA-labeled contraindications. A history of breast cancer and severe liver impairment are also label-level reasons Osphena should not be used. The coverage question is not your first question; that conversation belongs with your clinician.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The 2026 numbers that control the decision

The maximum 2026 Part D deductible is $615, and the annual out-of-pocket limit for covered Part D drugs is $2,100. Under the standard benefit, a beneficiary generally pays 25% after the deductible until reaching that limit, but many plans use lower deductibles, flat copays, or other approved designs.

2026 number	What it means
$615	The most a Medicare drug plan can charge as its annual deductible in 2026. Some plans charge less or have no deductible.
$2,100	The annual out-of-pocket limit for drugs covered under Part D. After you reach it, you pay $0 for covered Part D drugs for the rest of the calendar year.
25%	The standard-benefit coinsurance after the deductible and before the out-of-pocket limit. Your plan may instead use tiered copays or another approved design.
Up to $12.65	The 2026 price for each covered brand-name fill for most people who qualify for Extra Help and use a participating pharmacy.
$190 for 90 tablets	The current manufacturer-advertised Osphena at Home cash price when insurance does not cover Osphena or the patient has no insurance. The card contains a separate Medicare Part D cash-pay terms block, and the payment does not count toward Part D TrOOP.

Source: Medicare's 2026 Part D cost page, Medicare's 2026 Extra Help page, and the January 2026 Osphena Savings Options card.

Which kind of Medicare do you have?

Osphena's routine retail coverage comes from a Part D drug benefit—not from Original Medicare's ordinary Part A/B medical benefit. The first move is to identify whether you have a stand-alone Part D plan, an MA-PD plan, employer drug coverage, or no active drug coverage at all.

What you have	Can it cover a routine retail Osphena prescription?	Your first move
Original Medicare Part A and Part B only	Not through the routine retail-drug benefit. Part B covers only a limited set of outpatient drugs.	Find out whether you also have separate Part D coverage.
Original Medicare plus a stand-alone Part D plan	Possibly	Search that exact plan's current formulary.
Medicare Advantage with drug coverage, or MA-PD	Possibly	Search that plan's formulary and restriction documents.
Medicare Advantage without drug coverage	Not through that plan's drug benefit	Check whether you have another source of creditable drug coverage before changing anything.
Employer or retiree Medicare drug plan	Plan-specific	Use the group plan's formulary and benefits contact.
No active drug coverage	No Part D claim to run	Get free enrollment help before assuming cash is your only route.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What did The HRT Index actually verify for this page?

We verified the current FDA label, the current manufacturer savings card, four official 2026 Medicare formularies, four public payer criteria documents, Medicare's 2026 and 2027 benefit figures, the Part D exception and appeal clocks, and the FDA record for generic ospemifene. We did not turn a convenience sample into a national coverage rate.

What we read in full on August 27, 2026

• Osphena's current FDA label on DailyMed, version 4, revised February 2025: both approved uses, dosing, boxed warning, contraindications, warnings, interactions, clinical-trial results, packaging, and data in women age 65 and older.
• The January 2026 Osphena Savings Options card, document code OSP-2024-0004-04: every advertised lane, the general government-program exclusion, and the separate terms for Medicare Part D patients who choose to pay cash.
• Four official 2026 Medicare plan documents: KelseyCare Advantage, Quartz Medicare Advantage/D-SNP, UnitedHealthcare Group Medicare Advantage, and a Humana Medicare Employer abbreviated formulary.
• Four public payer criteria documents: CVS Caremark policy 961-A, Blue Cross Blue Shield of Arizona guideline P221.2, Centene policy CP.PMN.168, and the Iowa Medicaid Osphena prior-authorization form.
• Medicare's 2026 Part D cost rules, Extra Help rules, CMS exception rules, and Medicare drug-plan appeal deadlines.
• The FDA's February 2024 first-generic approval and the FDA Orange Book supplement that later marked Hetero's ospemifene product as discontinued from marketing.
• The 2026 Medicare Trustees Report, which sets the standard 2027 Part D deductible at $700 and the annual out-of-pocket threshold at $2,400.

What we could not verify—and will not pretend we did

• Your exact plan's tier, prior-authorization criteria, or pharmacy price.
• Your copay before a live claim or plan-specific estimate.
• A national Medicare coverage percentage. Four plan documents are a verification sample, not a survey.
• A currently marketed generic ospemifene product that a pharmacy can order today.
• Whether every AARP/UnitedHealthcare, Wellcare, or Humana plan treats Osphena as preferred. That is a current manufacturer statement, not a universal formulary promise.

Does Medicare cover Osphena under Part D?

Yes, Part D is allowed to cover Osphena. CMS clarified in 2018 that drugs used for moderate-to-severe dyspareunia due to menopause are not excluded from Part D when used consistently with their FDA labeling. That opens the door; it does not force every plan to list Osphena or approve every request.

The statute behind the question is Social Security Act §1860D-2(e)(2)(A). It excludes a drug when used to treat sexual or erectile dysfunction unless the drug is being used for another FDA-approved condition. In 2018, CMS clarified that menopause-related moderate-to-severe dyspareunia is not excluded when treated consistently with the drug's labeling. The International Society for the Study of Women's Sexual Health published the clarification on May 10, 2018.

Here is the line that matters:

Not excluded is not the same as covered.

CMS said Part D may cover these drugs. CMS did not assign Osphena one national tier, remove prior authorization, or require every formulary to list it. Your plan still controls:

• whether Osphena is on the formulary;
• the tier;
• prior authorization, step therapy, or quantity limits;
• the network pharmacy rules;
• how the deductible and benefit stage affect the price;
• what documentation is required in a coverage request.

The honest answer to “does Medicare cover Osphena?” is: the door is open, but your exact plan and claim decide whether it pays.

First move, two minutes: Pull out your drug-plan card. Find the plan name and plan year. Search the current formulary for both Osphena and ospemifene. Plan tools may use either name.

Run the five-question Osphena Part D Check ↓

What four real 2026 Medicare plan documents say about Osphena

In this four-document verification sample, all four 2026 Medicare plan documents listed Osphena and all four required prior authorization. Tier placement differed, and quantity limits appeared differently or were not shown in the shorter documents. This sample proves variation—not national prevalence.

Official 2026 plan document	Plan context	Osphena tier	Prior authorization	Quantity limit shown	Source date
KelseyCare Advantage Freedom HMO-POS and Signature HMO, formulary ID 26415	Medicare Advantage	Tier 3	Yes	30 tablets per 30 days	Updated July 1, 2026
Quartz Medicare Advantage and Dual Eligible 2026 Top-Drug Categories List	Medicare Advantage / D-SNP summary	Tier 3	Yes	Not shown in this summary	Document code GH00260C0725
UnitedHealthcare Group Medicare Advantage 2026 formulary, ID 00026005	Employer/group Medicare Advantage	Tier 2	Yes	Maximum one tablet per day	Updated October 15, 2025
Humana Medicare Employer Plan abbreviated 2026 formulary	Employer/group Medicare plan	Tier 3	Yes	Not shown in this abbreviated list	Updated September 3, 2025

What this sample proves

1. Osphena appears on real 2026 Medicare formularies. A statement that “Medicare never covers it” is wrong.
2. A formulary listing is not a clean pharmacy approval. All four documents showed prior authorization.
3. There is no national Osphena tier. The verified documents used Tier 2 and Tier 3.
4. “30 tablets per 30 days” and “maximum one tablet per day” describe the same daily allowance. Both align with the FDA-labeled once-daily dose.
5. Short lists hide detail. “Not shown” does not mean “not required.” The Quartz and Humana documents are summary or abbreviated lists; the full plan materials may contain more rules.

What this sample does not prove

It does not prove that every Part D plan covers Osphena, that prior authorization is universal, that a specific insurer treats every plan the same, or what you will pay. Two documents are employer/group formularies, and the sample is not statistically representative.

We refuse to publish a national coverage rate from four documents. You should be suspicious of any page that gives you one without showing the dataset, plan universe, release date, and deduplication method.

Check your plan against the same four fields ↓: tier, prior authorization, quantity limit, and pharmacy status.

Can the indication documented in a coverage request change the decision?

Yes. A retail pharmacy claim may not carry a diagnosis, but the indication documented by the prescriber can matter when a plan reviews prior authorization, a coverage determination, or an exception. Osphena has two FDA-approved uses, and public payer rulebooks do not treat them consistently.

Osphena's current FDA label lists:

1. moderate-to-severe dyspareunia, or painful sex, due to vulvar and vaginal atrophy from menopause;
2. moderate-to-severe vaginal dryness due to vulvar and vaginal atrophy from menopause.

Same drug. Same 60 mg tablet. Same once-daily dose. Different coverage language.

Four public payer criteria examples—not four Part D rules

Three documents below govern commercial, Marketplace, or Medicaid coverage. They do not control a Medicare Part D plan. They are included because they reveal how approval language diverges and why a denial may turn on what the prescriber accurately documents.

Public criteria document	Scope stated in the document	Painful sex approved?	Vaginal dryness approved?	Prerequisite treatment in the public criteria	Initial approval
CVS Caremark policy 961-A, P01-2025	Public Caremark PA policy; client applicability depends on the plan	Yes	Yes	No prerequisite treatment trial listed	12 months
Blue Cross Blue Shield of Arizona P221.2	Commercial and Marketplace only; explicitly excludes Medicare Advantage and Medicaid	Not listed as an approvable indication	Yes	Two estrogen-product trials unless an exception in the criteria applies	12 months
Centene CP.PMN.168	Public policy labeled Commercial, HIM, Medicaid; detailed PDF last reviewed November 2020	Yes	Yes	Two vaginal lubricants or moisturizers plus at least four weeks of one vaginal estrogen, unless excluded by the criteria	12 months for Medicaid/HIM; commercial length of benefit
Iowa Total Care Medicaid Osphena PA form	Iowa Medicaid managed care	No—the form says requests for dyspareunia will be denied	Yes	One preferred vaginal estrogen unless medically contraindicated	3 months

The number of prerequisite treatments in those public documents ranges from zero to three. That is not a national Medicare rule. It is proof that “prior authorization required” tells you almost nothing until you read the actual criteria.

Blue Cross Blue Shield of Arizona's guideline was reviewed and revised November 20, 2025. It applies only to commercial and Marketplace plans, yet its definitions section still says moderate-to-severe dyspareunia could be a benefit exclusion. That wording does not control Medicare Part D. But if a Part D denial uses similar “sexual dysfunction” language, ask the plan to identify the exact basis and issue a formal coverage determination. The 2018 CMS clarification is directly relevant to that question.

What to do—and what not to do

Do not ask anyone to record a diagnosis or symptom you do not have. That is not a loophole. It is false documentation.

Do make sure the record is complete and true. Some women have both vaginal dryness and pain; others have only one. If more than one symptom is genuinely present but the coverage request lists only one, tell the prescriber. The prescriber—not the patient, pharmacy, or this page—decides what is clinically accurate and belongs in the request.

Print the coverage-summary worksheet ↓. It carries both FDA-labeled uses, the Part D exclusion section, the plan fields to collect, and space for the prescriber's own supporting statement.

Osphena Part D Check: five questions to answer before you pay

You do not need your Medicare number, Social Security number, diagnosis, or full medical history to perform the first coverage check. You need five plan-and-claim facts. Once those are written down, “not covered” usually turns into a specific problem with a specific next move.

1. What kind of drug coverage do you have?

Write down one:

• stand-alone Part D plan;
• Medicare Advantage with drug coverage;
• employer or retiree Medicare drug plan;
• Medicare and Medicaid;
• no active drug coverage;
• not sure.

2. Is the drug listed under either name?

Search the current plan year for:

• Osphena;
• ospemifene;
• 60 mg tablet;
• NDC 55494-580-30 for the 30-tablet bottle or 55494-580-90 for the 90-tablet bottle, when the tool supports NDC search.

3. What tier and restriction codes appear?

Record:

• tier;
• PA, prior authorization;
• ST, step therapy;
• QL, quantity limit;
• NF, nonformulary;
• any mail-order or dispensing limit.

4. Which pharmacy and benefit stage are you using?

Record whether the pharmacy is:

• preferred network;
• standard network;
• out of network;
• mail order;
• unknown.

Then record whether the plan says your deductible is unmet, partly met, or met.

5. What did the live claim actually say?

Ask the pharmacy to run the prescription through the plan and give you:

• the full rejection text;
• the rejection code;
• quantity and days' supply submitted;
• the price through Part D;
• whether the quote was a plan claim or a cash transaction.

A cash quote is not a coverage decision.

Your result	What it usually means	Your next move
Drug listed; claim paid	Covered under the submitted conditions	Confirm the price, pharmacy status, and days' supply.
PA required	The plan wants coverage information	Get the exact criteria and ask whether the prescriber received the request.
ST required	The plan has prerequisite criteria	Get the criteria in writing; let the clinician decide what is appropriate.
QL exceeded	Quantity or days' supply exceeded the plan limit	Compare the submitted quantity with the plan's written limit.
Nonformulary	The drug is not routinely listed	Ask for covered options and the formulary-exception route.
Pharmacy not in network	The pharmacy—not necessarily the drug—is the problem	Locate an in-network or preferred pharmacy.
High price; claim paid	Covered, but deductible, tier, coinsurance, or pharmacy may be driving cost	Compare the full-year Part D route with cash before choosing.
Drug not found	Possible product or submission mismatch	Ask the pharmacy to verify the name, strength, and NDC.

Micro-commitment: do not decide anything yet. Get those five answers first.

How much does Osphena cost with Medicare in 2026?

There is no single Medicare price for Osphena. Your cost can range from the Extra Help copay for a covered brand-name fill to your plan's negotiated price before the deductible, and the exact amount changes with tier, pharmacy, benefit stage, and whether the claim is processed through Part D or as cash.

Here are the payment routes that can actually appear at the counter.

How you pay	Current amount or calculation	Can a Medicare beneficiary use it?	Counts toward Part D out-of-pocket spending?
Extra Help, or Low-Income Subsidy	Up to $12.65 per covered brand-name fill in 2026 at a participating pharmacy	Yes, if eligible	Yes
Your plan's tiered copay	The copay printed in your plan materials for that tier, pharmacy, and supply	Yes	Yes
Your plan's coinsurance	A percentage of the plan-negotiated price	Yes	Yes
Standard Part D benefit after the deductible	Generally 25% until covered out-of-pocket spending reaches $2,100	Yes	Yes
Osphena at Home Medicare cash-pay route	$190 for 90 tablets, or about $63.33 per 30 days	Yes, under the separate Medicare Part D cash-pay terms on the current card	No
Manufacturer commercial copay card	$35 for 30 tablets or $90 for 90 by mail; $45 for 30 at retail	No for anyone enrolled in Medicare, Medicaid, TRICARE, or another government healthcare program	Not applicable
GoodRx-processed cash lane printed on the manufacturer card	$85 for 30 tablets; $205 for 90 tablets; $2.28 per tablet for quantities over 60	Yes as a cash transaction, subject to current pharmacy and program terms	No

Source: Medicare Part D costs, Extra Help drug costs, and the January 2026 Osphena Savings Options card.

The $253 break-even number—used correctly

The $190 manufacturer cash lane works out to about $63.33 for 30 days. Under the standard post-deductible Part D benefit, 25% of a negotiated 30-day price exceeds $63.33 only when that negotiated price is above about $253.33.

The math is real. The conclusion still depends on your plan.

• If your plan charges 25% and the negotiated price is below $253.33, the covered claim is cheaper for that fill.
• If your plan charges a flat copay, use the copay—not the 25% formula.
• If the deductible has not been met, your immediate plan price can be much higher.
• If you are approaching the $2,100 annual out-of-pocket limit, a covered claim may be worth more across the year than a lower cash price today.
• If the drug is nonformulary and no exception is approved, there may be no covered spending to preserve.

The cheapest fill is not automatically the cheapest year. That is the decision most price pages skip.

Check Extra Help before you accept a high price

In 2026, Medicare lists these general Extra Help limits:

2026 Extra Help test	One person	Married couple living together
Annual income	$23,940	$32,460
Resources	$18,090	$36,100

The resource figures include Medicare's stated burial-expense allowance; Alaska and Hawaii use higher income limits. Some people qualify automatically through Medicaid, Supplemental Security Income, or a Medicare Savings Program; others can apply. Income and resource counting rules are more detailed than a two-row table, so do not disqualify yourself from memory or a rough internet number.

The highest-value move on this page may be free: apply for Extra Help through Social Security. We earn nothing from that link. If you qualify and Osphena is covered, the 2026 brand-name copay can be no more than $12.65 at a participating pharmacy.

What is the $190 Medicare cash-pay route—and what does it cost later?

The current Osphena card contains a separate terms block for Medicare Part D patients who choose to pay cash. It allows the $190-for-90-tablet route outside Part D, but no claim may be submitted for Part D reimbursement and the payment does not count toward your Part D True Out-of-Pocket total.

The card looks contradictory until you read both terms blocks.

The general savings-card terms exclude people enrolled in Medicare, Medicaid, TRICARE, or another government healthcare program. That exclusion applies to the commercial savings offers.

The same card then contains a separate heading for Medicare Part D patients who choose to pay cash. Under that block:

1. You pay outside the Medicare drug benefit.
2. You may not file—or have someone else file—a claim for Part D reimbursement.
3. The payment does not count toward your True Out-of-Pocket, or TrOOP, total.
4. The $190-for-90-tablet route is dispensed through PhilRx under the program's current terms.

That makes the cash route real. It also makes the tradeoff real.

When the cash route can make sense

• Your plan does not list Osphena, and a formulary exception has been denied.
• Your plan's current price is higher, you are unlikely to approach the $2,100 cap, and the cash amount is manageable.
• You need a temporary bridge while a coverage request is pending and understand that the purchase will not advance your Part D spending.
• You do not have active Part D coverage and have already checked whether enrollment help or Extra Help changes the decision.

When to slow down before paying cash

• You qualify—or may qualify—for Extra Help.
• You regularly reach the Part D out-of-pocket limit.
• You take other expensive covered drugs that could move you toward the limit.
• Your plan price is high only because the deductible has not been met.
• A preferred pharmacy, 90-day supply, prior authorization, or exception could lower the covered price.

Paying $190 outside Part D can solve this month's checkout problem and make the full-year drug bill worse. Run both paths before you choose.

Can I use the Osphena savings card if I'm on Medicare?

You cannot use the commercial Osphena copay offers while enrolled in Medicare. The January 2026 card excludes government-program enrollees from the commercial lanes, but it separately allows Medicare Part D patients to use the higher cash-pay route outside their benefit under specific terms.

Here is the current manufacturer-published price ladder.

Manufacturer-published route	Current published price	Available while enrolled in Medicare?	Part D claim?
Commercial insurance, Osphena at Home	$35 for 30; $90 for 90	No	No
Commercial insurance, retail pharmacy	As little as $45 for 30	No	No
No coverage or uninsured, Osphena at Home	$190 for 90	Yes under the separate Medicare cash-pay block	No
GoodRx-processed cash lane on the card	$85 for 30; $205 for 90; $2.28 per tablet over 60	Yes as cash, subject to current terms	No

The commercial card does not vanish because someone turns 65. It becomes unavailable when the person is enrolled in a disqualifying government healthcare program. That distinction matters for someone who delays Medicare or has unusual coverage timing.

The manufacturer card also states that Osphena is a preferred brand in Medicare Part D with AARP/UnitedHealthcare, Wellcare, and Humana. That is a January 2026 manufacturer statement, not proof about every plan sold under those sponsor names. Treat it as a lead: search your exact 2026 plan and run a live claim.

Before choosing a cash lane, compare it with your actual plan result: run the five-question Osphena Part D Check.

What tier is Osphena, and why does it need prior authorization?

There is no national Medicare tier for Osphena. It appeared on Tier 2 and Tier 3 in our four-document 2026 sample, and all four documents showed prior authorization. Prior authorization is a request for coverage information—not a final denial and not a clinical judgment that the prescription is wrong for you.

Plan documents compress the problem into codes. Here is what they mean.

Code	What it means	What to ask next
PA	Prior authorization	What are the exact criteria, and has the prescriber received the request?
ST	Step therapy	Which prerequisite treatment or documentation does the written policy require?
QL	Quantity limit	What quantity and days' supply did the pharmacy submit, and what does the plan allow?
NF	Nonformulary	What covered alternatives are listed, and how do I request a formulary exception?
B/D	Part B versus Part D determination	Which benefit does the plan say applies to this drug and use?
MO	Mail-order availability or requirement	Does mail order change cost, supply, or eligibility?
NDS or DL	Non-extended-day supply or dispensing limit	Am I limited to 30 days or another maximum supply?

The tier number is not the bill

A Tier 3 drug can have a flat copay in one plan and percentage coinsurance in another. Those produce very different prices. Ask whether your tier uses:

• a fixed copay;
• coinsurance;
• the deductible first;
• preferred versus standard pharmacy pricing;
• a different cost for 30- and 90-day supplies.

That answer is worth more than the tier number alone.

Prior authorization is common in the verified sample

All four 2026 plan documents we reviewed showed PA. That does not establish a national rate, but it means a PA rejection is not an unusual or final result. Get the criteria before deciding the plan said no.

Step therapy is where the rulebooks split

Some public payer criteria require vaginal lubricants, moisturizers, or a vaginal estrogen trial first. Others list no prerequisite treatment trial. These are plan-specific rules, and the alternatives are not interchangeable. Obtain the exact criteria and let the prescriber decide what is clinically appropriate.

Sample packs may not count under one public policy

Blue Cross Blue Shield of Arizona's current commercial/Marketplace guideline says patient use of samples is not accepted as evidence of starting therapy, continuing therapy, or completing an adequate trial and failure. That statement does not govern Medicare Advantage or Part D, because the guideline explicitly excludes those plans. It does show why a plan may want pharmacy claims or chart documentation rather than a verbal history.

Here's what this page can't tell you

No website can know your exact Osphena copay without your plan, plan year, pharmacy, benefit stage, and a live claim. This page can show you the rules, verified examples, and next moves. It cannot replace the contract that controls your coverage.

That is the first damaging admission.

The second is about price. The $190 cash route is current manufacturer advertising, not a permanent price guarantee. A plan can change its formulary. A pharmacy network can change. A manufacturer can replace its card. A generic can enter or leave the market. The date beside a number matters.

The third is about us.

The HRT Index reviews online menopause providers and may earn commissions from some of them. No telehealth company can make a Medicare plan cover Osphena. Not one. A provider can evaluate you, prescribe when clinically appropriate, and submit truthful documentation. The plan still decides the claim.

That is why almost every action on this page is non-affiliate: check the formulary, obtain the rejection, apply for Extra Help, request a coverage determination, or file an appeal. There is one clearly marked affiliate option later, only for the narrow reader whose actual bottleneck is access to a prescriber willing to evaluate the situation. Most readers should not need it.

If you came here for self-pay treatment rather than Medicare coverage, the HRT cost guide or vaginal estrogen guide will serve that intent better.

Your pharmacy said no. Here's what it actually meant.

A pharmacy rejection is usually not a final Medicare denial. “Not covered” can mean nonformulary, prior authorization, step therapy, quantity limit, network, refill timing, deductible, or a submission error. Each one has a different fix, and the exact rejection is the first fact you need.

Most people hear one sentence at the counter and leave. Do not fight seven possible problems at once. Name the one you have.

Step 1: Get the exact rejection

Ask the pharmacy for the full text and code. Record:

• date and time;
• pharmacy name and phone;
• drug name and NDC submitted;
• quantity and days' supply;
• plan price quoted;
• whether the transaction was run through Part D or as cash;
• the full rejection message;
• the code, if available.

A cash quote is not a formal plan decision.

Step 2: Match the rejection to the next move

What you were told	What it usually means	Your next move
Prior authorization required	The plan needs coverage information	Get the criteria and ask whether the prescriber received the request.
Step therapy required	The plan has prerequisite criteria	Get the written policy; ask the clinician what is appropriate.
Quantity exceeded	The submitted amount is above the limit	Compare the prescription and days' supply with the plan limit.
Not on formulary	Osphena is not routinely listed	Ask for covered alternatives and the formulary-exception route.
Refill too soon	Timing—not necessarily coverage—is blocking the fill	Ask for the next payable date and whether an override applies to your circumstances.
Pharmacy not in network	The pharmacy is the problem	Locate an in-network or preferred pharmacy.
High price; claim paid	Deductible, tier, coinsurance, or pharmacy may be driving cost	Compare annual Part D and cash routes before abandoning coverage.
Drug not found	Possible name, NDC, strength, or submission mismatch	Ask the pharmacy to verify Osphena 60 mg and the submitted NDC.

Ask the pharmacy to run a test claim when possible. It gives you the adjudicated price or rejection without requiring you to buy the fill.

Step 3: Ask for the right Medicare decision

These terms are related but not interchangeable:

• Coverage determination: a formal decision about whether the plan will cover or pay for the drug under its rules.
• Formulary exception: a request to cover a drug that is not on the formulary.
• Restriction exception: a request to waive a prior-authorization, step-therapy, or quantity-limit requirement in the individual case.
• Tiering exception: a request for lower cost sharing when the plan and drug tier permit it.

A prescriber's supporting statement is required for an exception. It is not required for every type of coverage determination.

For a standard request involving drug benefits, the plan generally has 72 hours to decide. An expedited decision is generally due within 24 hours when waiting could seriously jeopardize life, health, or the ability to regain maximum function. For an exception, the clock starts when the plan receives the prescriber's supporting statement.

Step 4: Appeal an unfavorable decision

A Level 1 Part D appeal is called a redetermination.

• You, your representative, or your prescriber generally have 65 days from the denial notice to file.
• A standard benefit appeal is generally decided within 7 days.
• An expedited benefit appeal is generally decided within 72 hours.
• If Level 1 is denied, the Level 2 request generally must be filed within 60 days of the decision.

Put the deadline on your calendar the day the notice arrives. A deadline that passes quietly can end the process without anyone reconsidering the drug.

The plan call script

“I'm calling about Osphena 60 mg. Please tell me the exact reason the claim was rejected: nonformulary, prior authorization, step therapy, quantity limit, network, refill timing, deductible, or another reason. What is my formulary ID? What tier is Osphena on? What are the written criteria? How do I request a coverage determination or exception? Please give me a reference number for this call.”

The message to your prescriber

“My Medicare drug plan rejected Osphena 60 mg for [exact reason]. The plan says it needs [prior authorization / an exception / specific documentation]. It accepts requests through [fax / portal / phone], and the case or reference number is [number]. Could you review whether submitting the requested information is appropriate, or whether a covered treatment would fit me better?”

That message does not tell a clinician what to write. It gives the office a specific, answerable task.

Build your printable Osphena denial checklist ↓

Printable Osphena denial checklist

Use this checklist after a rejected claim or written denial. It keeps the pharmacy result, plan criteria, prescriber request, and Medicare deadline in one place so the problem does not dissolve into four phone calls with no record.

Pharmacy record

• [ ] Date and time: ____________________
• [ ] Pharmacy and phone: ____________________
• [ ] Osphena 60 mg submitted: yes / no
• [ ] NDC submitted: ____________________
• [ ] Quantity: ______ tablets
• [ ] Days' supply: ______ days
• [ ] Part D price quoted: $________
• [ ] Cash price quoted: $________
• [ ] Full rejection text: ________________________________
• [ ] Rejection code: ____________________

Plan record

• [ ] Plan name: ____________________
• [ ] Plan year: ____________________
• [ ] Contract and plan ID: ____________________
• [ ] Formulary ID: ____________________
• [ ] Tier: ____________________
• [ ] PA / ST / QL / NF / other: ____________________
• [ ] Preferred pharmacy confirmed: yes / no
• [ ] Written criteria obtained: yes / no
• [ ] Plan representative: ____________________
• [ ] Call reference number: ____________________

Prescriber record

• [ ] Office received the request: yes / no
• [ ] Supporting statement required: yes / no
• [ ] Request submitted on: ____________________
• [ ] Submission method: fax / portal / phone / other
• [ ] Office contact: ____________________

Deadline record

• [ ] Coverage determination requested: ____________________
• [ ] Standard decision due: ____________________
• [ ] Expedited decision due: ____________________
• [ ] Denial notice date: ____________________
• [ ] Level 1 appeal deadline, generally 65 days later: ____________________
• [ ] Level 1 submitted: ____________________
• [ ] Level 2 deadline, if needed: ____________________

Sources: CMS coverage determinations, CMS exceptions, and Medicare drug-plan appeals.

Printable Osphena coverage summary for your appointment

Bring one page, not a story your prescriber's office has to reconstruct. This summary gives the office the exact drug, plan fields, rejection, governing Medicare question, and submission route while leaving the medical reasoning to the clinician.

Drug facts

Field	Verified detail
Brand	Osphena
Generic name	ospemifene
Strength and form	60 mg oral tablet
Labeled dosing	One tablet daily with food
FDA application	NDA 203505
30-tablet NDC	55494-580-30
90-tablet NDC	55494-580-90
FDA-labeled use 1	Moderate-to-severe dyspareunia due to vulvar and vaginal atrophy from menopause
FDA-labeled use 2	Moderate-to-severe vaginal dryness due to vulvar and vaginal atrophy from menopause

Source: current Osphena prescribing information on DailyMed.

Plan and claim facts

Field	Fill this in
Plan name and year	______________________________
Contract and plan ID	______________________________
Formulary ID	______________________________
Drug listed as	Osphena / ospemifene / neither
Tier	______________________________
Restriction	PA / ST / QL / NF / other
Pharmacy status	Preferred / standard / out of network / unknown
Quantity and days' supply	______________________________
Part D price	$______________________________
Exact rejection	______________________________
Plan criteria URL or document	______________________________
Plan contact and case number	______________________________
Request channel	Fax / portal / phone / other
Decision deadline	______________________________

The Medicare question

Part D excludes drugs used for sexual or erectile dysfunction except when the drug is used for another FDA-approved condition. In 2018, CMS clarified that drugs approved for moderate-to-severe dyspareunia due to menopause are not excluded when used consistently with the FDA-approved labeling. “Not excluded” permits Part D coverage; it does not force a plan to list Osphena or approve every request.

Sources: Social Security Act §1860D-2(e)(2)(A) and the 2018 CMS clarification reported by ISSWSH.

Prescriber section

• Clinical indication documented: ______________________________
• Relevant prior treatment or contraindication, if truthful and applicable: ______________________________
• Reason the requested drug or exception is clinically appropriate: ______________________________
• Supporting statement sent on: ______________________________
• Prescriber or office contact: ______________________________

Do not fill the clinical section for the prescriber. Bring the plan's actual criteria and let the clinician decide what is accurate and medically supportable.

Is there a generic Osphena?

FDA approved a first generic ospemifene 60 mg tablet in February 2024, but approval does not prove a pharmacy can order it today. A later FDA Orange Book supplement marked Hetero's product as discontinued from marketing, and we could not verify a currently marketed generic as of August 27, 2026.

This is why the answers online look contradictory. They are often answering different questions.

The verified sequence

1. February 13, 2024: FDA approved Hetero Labs' ospemifene 60 mg tablet as the first generic for Osphena.
2. Later FDA record: an Orange Book cumulative supplement marked Hetero's ANDA 215574 with DISC, meaning discontinued from marketing.
3. August 27, 2026: we could not verify a currently marketed generic product available for routine pharmacy ordering.

Four facts people collapse into one

Statement	What it actually means
Ospemifene is the generic name	That is the nonproprietary name of the drug. It says nothing about a generic product being sold.
A generic was FDA-approved	FDA approved a specific abbreviated new drug application. True since February 2024.
A generic is marketed and available	A manufacturer is currently selling it and a pharmacy can order it. We could not verify that status.
A generic is covered	The exact plan lists the marketed product or NDC. That is a separate formulary question.

The safe pharmacy question is not “Is there a generic?” Ask:

“Can you order an FDA-approved ospemifene 60 mg generic today? Which manufacturer and NDC? What is the cash price, and does my plan list that exact product?”

If the answer changes, the price and formulary sections of this page change with it. That is why generic marketing status is on our monthly verification list.

Sources: FDA's 2024 first-generic approvals and the FDA Orange Book data files.

What if Osphena isn't on your plan's list at all?

If Osphena is truly nonformulary, your three immediate routes are a formulary exception, a cash purchase with no Part D out-of-pocket credit, or a clinician-guided covered option. During the applicable enrollment window, a fourth route is choosing a plan that covers your full medication list—not Osphena alone.

First, make sure it is truly absent

Check all of these before accepting “not on the list”:

• the correct plan year;
• the exact plan and formulary ID;
• Osphena;
• ospemifene;
• the 60 mg strength;
• NDC 55494-580-30 and 55494-580-90, if the tool accepts NDCs;
• the plan's most recent formulary update;
• a live pharmacy claim.

An online formulary search and a live claim can disagree because the wrong plan, year, product, or NDC was selected. Get the adjudicated reason.

Route 1: Request a formulary exception

Ask the plan for its exception form and the exact supporting-statement requirement. The prescriber must explain why the requested drug is medically necessary under the plan's rules. Approval is individual; no page or provider can promise it.

Route 2: Pay cash with the tradeoff visible

The current manufacturer route is $190 for 90 tablets through PhilRx under the separate Medicare cash-pay terms. That payment cannot be submitted to Part D and does not count toward TrOOP.

Route 3: Ask about covered treatment categories

Ask the prescriber which covered option—if any—fits the same clinical problem. Do not substitute on your own. Osphena, local vaginal estrogen, vaginal prasterone, moisturizers, and lubricants are not interchangeable products.

Route 4: Compare plans when you are allowed to switch

During Medicare Open Enrollment, compare:

• every prescription you take;
• the exact drug, strength, and quantity;
• estimated annual drug cost;
• premium and deductible;
• PA, ST, and QL;
• preferred pharmacies;
• mail order;
• whether the plan's estimate assumes a covered claim.

A plan that looks perfect for Osphena can be expensive overall once the rest of your medications are entered. Use Medicare Plan Compare and consider free help from your local State Health Insurance Assistance Program.

What changes for Osphena coverage in 2027?

The national Part D benefit changes in 2027, but Osphena's formulary position will still be plan-specific. The standard deductible rises from $615 to $700, and the annual out-of-pocket threshold for covered Part D drugs rises from $2,100 to $2,400. Your plan can also change the drug's tier, restrictions, or pharmacy network.

Standard Part D parameter	2026	2027
Maximum deductible	$615	$700
Annual out-of-pocket threshold for covered Part D drugs	$2,100	$2,400

Source: 2026 Medicare Trustees Report.

Put these dates on your calendar

Date	What to do
By September 30, 2026	Read the Annual Notice of Change from your current plan. Check whether Osphena's formulary status, tier, restrictions, and pharmacy network change for 2027.
October 1, 2026	Start reviewing available 2027 plan information and enter your complete medication list in Plan Compare.
October 15–December 7, 2026	Medicare Open Enrollment. Join, switch, or drop eligible Medicare health or drug coverage for a January 1 start.
January 1, 2027	The new plan year, deductible, formulary, and out-of-pocket tally begin.

Medicare confirms that Open Enrollment runs from October 15 through December 7 and changes take effect January 1 when the plan receives the enrollment request by December 7. See Medicare's Open Enrollment page.

Do not change plans for one drug in isolation. Enter Osphena plus every other medication, the pharmacies you use, and the supply you expect. Compare estimated annual cost—not premium alone.

What lower-cost treatment categories should you ask about?

Several public payer policies require a local option before approving Osphena, and Medicare formularies can list each product differently. Those products are different medications with different routes, labels, risks, and uses. This is a clinician conversation—not a substitution chart.

Treatment category	Route	Practical coverage question
Estradiol vaginal cream	Vaginal cream	Which strength and product does my plan list, and at what tier?
Estradiol vaginal tablet or insert	Vaginal insert	Which product is listed, and is there a quantity or dispensing limit?
Vaginal estrogen ring	Vaginal ring	How does the plan price one ring, and is prior authorization required?
Vaginal prasterone	Vaginal insert	Is it on the formulary, and what restrictions apply?
Ospemifene, or Osphena	Oral tablet taken daily with food	Is the brand listed, what tier is it, and what PA criteria apply?
Vaginal moisturizers and lubricants	Nonprescription vaginal or vulvar products	What symptom role can these play, and are they enough for my situation?

Two rules matter here.

First, these are not equivalent products. Do not infer that a lower tier makes an option medically preferable or that one can replace another without a clinician's assessment.

Second, the current Osphena label says not to use it at the same time as estrogens or other estrogen agonist/antagonists. “Add Osphena on top” is not a coverage workaround. The prescriber decides whether to stop, switch, or use another path.

A local option may be worth asking about when cost is the barrier, vaginal use is acceptable, and the clinician considers it appropriate. Osphena may remain worth pursuing when an oral route is important, local products are not a fit, or the clinician has another reason for choosing it.

Not sure which route belongs in your conversation? Use Find My HRT Path for a personalized starting point and a flag for situations that belong with an in-person clinician first.

Is Osphena worth fighting for? What the FDA label actually shows

Osphena improved moderate-to-severe dyspareunia versus placebo in both 12-week trials that measured that endpoint. For vaginal dryness, two trials showed a significant improvement and one did not. The same label carries a boxed warning for endometrial cancer and cardiovascular disorders, so coverage and medical suitability are separate decisions.

We would rather you pursue coverage with clear eyes than with a page that prints only the favorable results.

What the trials showed

• Dyspareunia: Trials 1 and 2 showed statistically significant improvement with Osphena 60 mg compared with placebo.
• Vaginal dryness: Trials 1 and 3 showed statistically significant improvement. Trial 2 did not.

That null result belongs on the page. It does not erase the approved indication. It stops the evidence section from becoming an advertisement.

The boxed warning is not fine print

The label's boxed warning covers:

• endometrial cancer risk because Osphena has estrogen-agonist effects in the endometrium and unopposed estrogenic activity increases risk;
• cardiovascular disorders, including stroke and deep-vein thrombosis risk.

The patient information tells women to report unusual vaginal bleeding after menopause and lists urgent symptoms associated with stroke and blood clots.

“Not a hormone” does not mean “low risk”

The prescribing information says Osphena is not a hormone and classifies ospemifene as an estrogen agonist/antagonist that acts differently across tissues. It is an oral systemic drug with a boxed warning.

Not a hormone is not the same as risk-free. Any page that lets those phrases blur is doing the reader a disservice.

Who should not take Osphena under the label

The formal contraindications include:

• undiagnosed abnormal genital bleeding;
• known or suspected estrogen-dependent neoplasia;
• active or past deep-vein thrombosis or pulmonary embolism;
• active or past arterial thromboembolic disease, including stroke and myocardial infarction;
• hypersensitivity to Osphena or its ingredients;
• known or suspected pregnancy.

The label also says Osphena should not be used in women with known, suspected, or a history of breast cancer, and it should not be used in severe hepatic impairment. Those are serious label-level restrictions, even though they appear outside the formal contraindications list.

What the label says about women age 65 and older

Across ten phase 2/3 trials, more than 19% of the 2,209 women treated with Osphena were age 65 or older. The label reports no clinically meaningful differences in safety or effectiveness between women 65 and older and younger women.

That is useful evidence for a Medicare-age conversation. It is not a reason to ignore an individual's risk history.

Common adverse reactions in trials up to 52 weeks

Adverse reaction	Osphena 60 mg	Placebo
Hot flush	12.2%	4.2%
Vaginal discharge	6.0%	0.6%
Muscle spasms	4.5%	2.4%
Hyperhidrosis, or increased sweating	2.5%	1.8%
Vaginal hemorrhage	1.3%	0%
Night sweats	1.2%	0%

Take Osphena with food; the label says food increases its bioavailability by approximately two- to threefold. The label says not to use it with fluconazole or rifampin and not to combine it with estrogens or another estrogen agonist/antagonist.

Source for this section: current FDA-approved Osphena labeling on DailyMed.

Coverage is not suitability. A plan's decision to list, restrict, or exclude Osphena is an insurance decision. Your clinician decides whether the drug fits your medical situation.

What if your prescriber will not submit the supporting statement?

An exception cannot move without the prescriber's supporting statement, but a paid second opinion should be a last step—not the first. Start by giving the current office the exact rejection, written criteria, submission channel, case number, and deadline. That turns “insurance said no” into a task the office can act on.

Ask the current office first. Send:

• the exact rejection;
• the plan's criteria document;
• the form or portal link;
• the case or reference number;
• the standard or expedited deadline;
• the concise message template from this page.

A second clinical opinion may be reasonable when the current prescriber will not evaluate the request, the documentation is incomplete and cannot be addressed in time, or you want a fresh assessment of whether Osphena or another route fits you. It does not guarantee a prescription, supporting statement, approval, or lower medication price.

The honest limitation before the only provider CTA on this page

Midi Health is not covered by Medicare or a Medicare-related insurance plan. Medicare beneficiaries may use Midi as self-pay patients but cannot submit claims related to Midi visits, medications, or associated services. Midi's current published self-pay price is $250 for an initial visit and $150 for continued-care visits. Midi also says it cannot treat Medicaid or Medi-Cal patients, even as self-pay.

That is roughly four months of the current $63.33-per-month manufacturer cash price before medication cost. For most readers, paying for a new visit solely to chase one coverage letter is the wrong move.

For the narrow reader whose true bottleneck is access to a menopause clinician who will independently evaluate the situation—not a guaranteed letter—Midi is a legitimate self-pay option.

Does that sound like your situation? Check Midi Health's current self-pay pricing and availability →

Affiliate disclosure: we may earn a commission if you book through this link. It does not change what you pay. Midi does not bill Medicare, and no clinician or coverage outcome is guaranteed. See our affiliate disclosure.

What women say about Osphena and insurance

The recurring language is not “I decided against it.” It is “insurance stopped covering it” or “insurance won't cover it.” These comments show the trigger behind this search; they are not verified plan records, medical evidence, or proof that another reader will receive the same result.

“Yup, my insurance company stopped covering Prempro and Osphena.”

— 1xbittn, r/Menopause discussion

“There was a tablet my doctor wanted me to take, Osphena, but insurance won't cover it.”

— a forum member, Well-Trained Mind forum, May 2023

Those sentences are exactly why “call your plan” is not enough. The reader needs to know whether the problem is the formulary, a restriction, the pharmacy, the deductible, or a missing formal request.

The quotes above are included for voice-of-customer language only. They do not support a medical, safety, effectiveness, price, or coverage claim.

Your situation → your next move

Everything on this page reduces to a small number of situations. Find the row that matches the actual plan or claim result, take the single next action beside it, and do not solve a different problem than the one in front of you.

Where you are now	What it means	What to do next
Covered at a manageable price	The claim paid under the submitted conditions	Confirm the supply and pharmacy, then fill under your prescriber's instructions.
Covered, but PA is required	Coverage information is missing	Get the criteria and send the prescriber the case number and request channel.
Denied with sexual-dysfunction language	The plan may be applying or describing the exclusion broadly	Request a formal coverage determination and ask the plan to identify the legal and formulary basis.
Step therapy required	The plan has prerequisite criteria	Obtain them in writing and ask the clinician what is medically appropriate.
Quantity limit exceeded	The submitted amount or days' supply is outside the rule	Compare the prescription with the exact limit and ask about an appropriate override if circumstances warrant.
Not on the formulary	The plan does not routinely list Osphena	Request an exception; compare the cash tradeoff and clinician-guided covered options.
Cash is cheaper today	The Part D and cash routes are not the same transaction	Compare the full-year effect, especially Extra Help and progress toward the $2,100 cap.
Medicare plus Medicaid	Drug coverage and cost-sharing rules may be coordinated	Ask the plan or SHIP which benefit and rules apply; do not rely on a commercial or single-state policy.
Income or resources near Extra Help limits	The largest price reduction may be outside the formulary fight	Apply through Social Security rather than ruling yourself out from a rough estimate.
No active drug coverage	There is no Part D claim to fix	Get unbiased enrollment help and check for a Special Enrollment Period before defaulting to cash.

Frequently asked questions

These answers close the remaining Medicare, price, restriction, generic, and appeal questions in plain language. Each one gives the direct answer first, then the condition that can change it for a specific plan or person.

Does Original Medicare cover Osphena?

Original Medicare Parts A and B do not normally cover a routine retail Osphena tablet taken at home. Coverage may come through a separate Part D plan or a Medicare Advantage plan that includes prescription-drug coverage.

Does Medicare Part D cover Osphena?

It can. Osphena is not automatically excluded from Part D when used consistently with its FDA labeling for menopause-related moderate-to-severe dyspareunia, but each plan decides whether to list it, which tier to use, and which restrictions apply. All four 2026 plan documents in our verification sample listed it and required PA.

Does Medicare Advantage cover Osphena?

A Medicare Advantage plan can cover a routine retail Osphena prescription when the plan includes Part D drug coverage. Search the exact MA-PD formulary and restriction document; an insurer's name alone is not enough.

What tier is Osphena on Medicare?

There is no national tier. The four verified 2026 documents used Tier 2 or Tier 3. Ask whether the tier uses a flat copay or coinsurance and whether the deductible and preferred-pharmacy rules apply.

How much does Osphena cost with Medicare?

There is no universal Medicare price. The exact amount depends on formulary status, tier, deductible, pharmacy, supply, Extra Help, and benefit stage. Under Extra Help, a covered brand-name fill costs no more than $12.65 for most qualifying beneficiaries in 2026 at a participating pharmacy.

Can I use the Osphena commercial coupon with Medicare?

No. The current commercial savings terms exclude anyone enrolled in Medicare, Medicaid, TRICARE, or another government healthcare program. The same card contains a separate, higher cash-pay route for Medicare Part D patients who pay outside their benefit.

Does the $190 cash price count toward my $2,100 Part D limit?

No. The manufacturer terms say no Part D reimbursement claim may be filed and the cash payment does not count toward TrOOP. That is the main annual-cost tradeoff.

Can I use GoodRx instead of Part D?

You can use a participating cash discount instead of the Part D claim for that transaction, subject to current terms and pharmacy acceptance. You cannot combine the two prices, and the cash payment should not be treated as progress toward the Part D deductible or out-of-pocket limit.

Does Osphena require prior authorization?

It did in all four 2026 plan documents we verified. That does not make PA universal. Check your exact formulary and criteria. PA means the plan wants information before it pays; it is not the final decision.

Is there a generic Osphena?

FDA approved a first generic ospemifene in February 2024, but a later Orange Book supplement marked that product discontinued from marketing. We could not verify a currently marketed generic as of August 27, 2026. Ask the pharmacy for a manufacturer and NDC before assuming one is available.

Can I take Osphena with vaginal estrogen?

The current label says not to use Osphena with estrogens or other estrogen agonist/antagonists. Do not add, stop, or switch either medication on your own; that is a clinician decision.

Does Extra Help make Osphena cheaper?

It can make a covered brand-name fill cost no more than $12.65 in 2026 for most qualifying beneficiaries at participating pharmacies. Extra Help lowers cost sharing; it does not force a plan to list or approve a drug.

Does the Medicare Prescription Payment Plan lower Osphena's total price?

No. It can spread eligible Part D out-of-pocket costs across monthly bills, but it does not reduce the total drug cost. A purchase made outside Part D is not converted into a covered claim by joining the payment plan.

How long does an Osphena exception take?

A standard benefit decision is generally due within 72 hours and an expedited decision within 24 hours. For an exception, the clock starts when the plan receives the prescriber's supporting statement. If denied, the Level 1 appeal window is generally 65 days.

Will a different pharmacy be cheaper?

It can be. A preferred, standard, mail-order, and out-of-network pharmacy can produce different Part D prices and dispensing rules. Check the plan's network and run a live claim before moving the prescription.

What changes for Osphena in 2027?

The standard Part D deductible rises to $700 and the annual out-of-pocket threshold rises to $2,400. The more important drug-specific question is whether your plan changes Osphena's formulary status, tier, PA, QL, or pharmacy terms. Read the Annual Notice of Change and compare 2027 plans during Open Enrollment.

The bottom line

Medicare can cover Osphena through Part D or a Medicare Advantage drug plan. Whether your plan pays depends on the formulary, restrictions, pharmacy, benefit stage, and truthful documentation supporting any coverage request. If the claim fails, get the exact rejection before deciding that cash or a different medication is your only move.

Do these in order:

1. Confirm that you have active prescription-drug coverage.
2. Search the current formulary for both Osphena and ospemifene.
3. Record the tier, PA, ST, QL, and pharmacy status.
4. Ask the pharmacy to run a live claim and give you the exact result.
5. Send the prescriber the written criteria, case number, and submission route—not just “insurance said no.”
6. Apply for Extra Help if your income or resources may be close to the limits.
7. Compare cash only after you understand the lost Part D out-of-pocket credit.
8. If the plan truly does not list Osphena, request an exception and compare the full medication list during an eligible plan-change window.

You are not being difficult. You are asking a health plan to make a formal decision about an FDA-approved prescription for a documented menopausal condition. That is ordinary. It is worth asking twice.

How we verified this

Every material medical, coverage, price, and timing claim on this page traces to a dated primary or official source. We record what each document proves, refuse to turn small samples into national rates, and leave unresolved facts labeled rather than selecting the answer that converts best.

The HRT Index Verification Standard is our documented process: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, the full roster quarterly. For a drug-coverage page, we apply the same standard to labels, benefit rules, formularies, payer criteria, and manufacturer terms: read the primary source, record the fields without extrapolating, date the claim, and state what the document cannot prove.

We evaluate providers and care paths on exactly five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish numeric provider scores.

Primary and official documents used

• Osphena FDA-approved labeling on DailyMed, version 4, revised February 2025.
• Osphena Savings Options card, OSP-2024-0004-04, January 2026.
• Medicare Part D costs, Extra Help costs and eligibility, and Medicare Open Enrollment.
• CMS coverage determinations, exceptions, and Medicare Part D appeals.
• Social Security Act §1860D-2 and the 2018 CMS clarification reported by ISSWSH.
• Official 2026 formularies linked in the four-plan verification table.
• Public payer criteria linked in the indication table.
• FDA's 2024 first-generic approvals and Orange Book data.
• Midi Health's current pricing and Medicare terms, checked August 27, 2026.

Refresh schedule

Element	Re-check cadence
Osphena FDA label and NDCs	Monthly
Generic ospemifene marketing status	Monthly until a marketed product is verified
Manufacturer prices and Medicare cash terms	Monthly
Highlighted plan formularies and payer criteria	Quarterly and after a plan update
Medicare annual deductible, out-of-pocket limit, Extra Help figures, and enrollment dates	Annually and when CMS publishes the next year
Midi self-pay price and Medicare status	Quarterly and on publication day
Cash-discount prices	At the point of use; never publish as a permanent pharmacy price

Found a current document that conflicts with this page? Send the source and effective date through our corrections page. We change the “Last verified” date only after re-checking the affected claim.

Who wrote this: The HRT Index Editorial Team. This is editorial research and educational information, not medical advice, and it has not been reviewed by a clinician. See our medical review policy. Talk with your clinician before starting, stopping, combining, or changing any medication.

The HRT Index is not affiliated with or endorsed by Medicare, CMS, the Social Security Administration, FDA, or the U.S. government.

---

Still not sure which HRT program is right for you? Take our free matching quiz — it takes about 90 seconds.

Find My HRT Path →

Get a personalized starting point based on your symptoms, medication-route preference, insurance situation, and state—including a flag for when online care is not the right first step.

Find My HRT Path handles sensitive health information under our consumer health data privacy policy.